8/4/2009 | SS | EPIX Pharmaceuticals ready to sell equipment, intellectual property
|
7/20/2009 | CVDD | EPIX Pharmaceuticals to liquidate under Massachusetts assignment
|
7/10/2009 | CV | EPIX buys back $3.12 million of 3% convertible senior notes due 2024
|
7/10/2009 | PP | EPIX, Kingsbridge end $50 million equity financing facility agreement
|
6/3/2009 | CV | EPIX Pharmaceuticals holders may put back 3% convertibles on Aug. 5
|
5/20/2009 | CVDD | EPIX Pharmaceuticals stock delisted from Nasdaq; holders may put back convertibles at par
|
5/5/2009 | CVDD | EPIX Pharmaceuticals holders tender nearly 97% of 3% convertibles in exchange offer
|
4/7/2009 | CVDD | EPIX Pharmaceuticals begins exchange offer for 3% convertibles in attempt to avoid bankruptcy
|
3/13/2009 | CVDDPPSS | EPIX Pharmaceuticals needs capital to fund operations after August, convertibles redemption
|
3/12/2009 | CV | EPIX says $100 million of convertibles may be due after non-compliance with Nasdaq
|
8/5/2008 | PP | New Issue: EPIX commits to $50 million equity financing with Kingsbridge
|
8/5/2008 | PP | Market Commentary: Acadia gets $60 million; EPIX arranges $50 million; RoomLinX, Admiralty advance funding efforts
|
11/12/2007 | PP | New Issue: EPIX negotiates $16.3 million private placement of stock
|
11/12/2007 | PP | Market Commentary: InterOil wraps $10 million; EPIX negotiates $16.3 million; St Andrew plans C$20 million
|
12/22/2006 | CV | EPIX Pharmaceuticals files $75 million shelf registration
|
10/30/2006 | BT | Epix planning to secure at least one partnership by end of 2007
|
9/21/2006 | BT | Epix: PRX-00023 fails phase 3 anxiety trial
|
8/28/2006 | BT | EPIX imaging agent Vasovist denied; FDA urges two new clinical trials
|
8/28/2006 | BT | Market Commentary: Discovery Partners up 9% on MedImmune, Infinity pact; EPIX plunges; Sinovac soars; PDL up
|
7/28/2006 | BT | EPIX gets extension on FDA review of Vasovist
|
7/13/2006 | BT | EPIX retains full rights to EP-2104R; Schering decides not to exercise option
|
6/30/2006 | BT | EPIX files appeal with FDA in response to Vasovist approvable letter
|
5/26/2006 | BT | Market Commentary: Anadys spikes on thin volume; Cubist extends gain on Cubicin nod; Tanox, Momenta, Epix up
|
5/3/2006 | BT | Predix receives patent on 5-HT receptor antagonists, related treatment of serotonin disorders
|
5/1/2006 | BT | EPIX first-quarter net loss shrinks to $4.5 million, revenue declines
|
4/3/2006 | BT | EPIX to acquire Predix in $90 million transaction
|
4/3/2006 | BT | Market Commentary: Epix up 21% on Predix buy; Incyte falls 41%; Medarex off; Inhibitex plunges 66%; StemCells dives
|
2/16/2006 | BT | EPIX's 2005 results reveal drop in revenue, increased losses
|
2/13/2006 | BT | EPIX Pharmaceuticals gets patent for EP-2104R
|
2/10/2006 | BT | Schering exercises option with EPIX to develop preclinical gadofluorine derivative
|
1/3/2006 | BT | EPIX accelerates phase 2a study of blood clot imaging agent
|
12/16/2005 | BT | EPIX hires consulting firm to identify acquisition target, puts attorney on staff to assist in transaction
|
12/13/2005 | BT | EPIX to cut workforce 50% after FDA fails to approve Vasovist
|